Published in Cancer on June 01, 1980
Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science (1999) 36.25
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol (2007) 7.33
COP1, an Arabidopsis regulatory gene, encodes a protein with both a zinc-binding motif and a G beta homologous domain. Cell (1992) 5.58
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA (1994) 4.01
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med (1994) 3.89
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
A genome-wide screen in Saccharomyces cerevisiae for genes affecting UV radiation sensitivity. Proc Natl Acad Sci U S A (2001) 2.49
A physiologic approach to laparoscopic fundoplication for gastroesophageal reflux disease. Ann Surg (1996) 2.49
Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery (1970) 2.34
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol (1995) 2.33
Fatty acid composition of the subcutaneous adipose tissue and risk of proliferative benign breast disease and breast cancer. J Natl Cancer Inst (1993) 2.15
Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys (1990) 2.11
Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg (1981) 1.86
Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72
Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann Surg (1970) 1.68
Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. Cancer (1985) 1.62
Skin-sparing mastectomy. Oncologic and reconstructive considerations. Ann Surg (1997) 1.61
Clinical validation of an autoantibody test for lung cancer. Ann Oncol (2010) 1.55
Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol (2000) 1.54
Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. Ann Surg (1999) 1.51
Early discharge after modified radical mastectomy. Am J Surg (1986) 1.47
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol (1996) 1.43
A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann Surg (1981) 1.38
Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg (1982) 1.38
Carcinoid tumors of the appendix. Ann Surg (1993) 1.36
A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery (1981) 1.33
Sarcomas of the gastrointestinal tract. Separation into favorable and unfavorable prognostic groups by mitotic count. Ann Surg (1991) 1.30
Radiation therapy of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys (1984) 1.30
Treatment of the patient with stage M0 soft tissue sarcoma. J Clin Oncol (1988) 1.29
Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192). Am J Clin Oncol (2001) 1.26
Intraoperative electron beam radiation therapy for primary locally advanced rectal and rectosigmoid carcinoma. J Clin Oncol (1991) 1.26
A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg (1982) 1.24
Preoperative radiation therapy for sarcoma of soft tissue. Cancer (1981) 1.12
Intraoperative electron beam radiation therapy for retroperitoneal soft tissue sarcoma. Cancer (1991) 1.11
Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg (1984) 1.11
Intraoperative irradiation for unresectable pancreatic carcinoma. Cancer (1982) 1.11
Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther (2004) 1.11
Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst (1995) 1.09
Postoperative radiation therapy of rectal cancer. Int J Radiat Oncol Biol Phys (1987) 1.08
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol (1996) 1.07
Residual, unresectable, or recurrent colorectal cancer: external beam irradiation and intraoperative electron beam boost +/- resection. Int J Radiat Oncol Biol Phys (1983) 1.04
Pathological studies in rectal cancer. Cancer (1980) 1.03
A prognostic model for clinical stage I melanoma of the trunk. Location near the midline is not an independent risk factor for recurrent disease. Am J Surg (1981) 1.01
Host immune response to a common cell-surface antigen in human sarcomas. N Engl J Med (1971) 1.01
Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trials. Arch Surg (1986) 1.01
Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol (2000) 0.98
The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma. J Clin Oncol (1987) 0.98
Treatment of early stage breast cancer by limited surgery and radical irradiation. Int J Radiat Oncol Biol Phys (1980) 0.97
Benign smooth muscle tumors of the gastrointestinal tract. A 24-year experience. Ann Surg (1990) 0.97
Predictors of late deaths among patients with clinical stage I melanoma who have not had bony or visceral metastases within the first 5 years after diagnosis. J Am Acad Dermatol (1983) 0.96
Patterns of failure following local excision and local excision and postoperative radiation therapy for invasive rectal adenocarcinoma. J Clin Oncol (1989) 0.96
Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer. Eur J Cancer (1995) 0.96
The management of ductal and lobular breast cancer. Surg Oncol (1999) 0.95
Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol (1999) 0.92
Extra-hepatic biliary tract metastases from breast cancer. Int J Radiat Oncol Biol Phys (1980) 0.91
Irradiation of nasopharyngeal carcinoma: correlations with treatment factors and stage. Int J Radiat Oncol Biol Phys (1984) 0.91
Treatment of hepatic metastases by transaxillary hepatic artery chemotherapy using an implanted drug pump. Cancer (1983) 0.90
Reversal of selenium deficiency with oral selenium. N Engl J Med (1981) 0.90
Regional hepatic chemotherapy using an implantable drug infusion pump. Am J Surg (1983) 0.89
Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081. Cancer (1988) 0.89
pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival. Breast Cancer Res Treat (1992) 0.89
Cytotoxic antibody responses in astrocytoma patients. An improved allogeneic assay. J Neurosurg (1979) 0.89
Intraoperative electron beam radiotherapy in the treatment of unresectable rectal cancer. Arch Surg (1986) 0.88
Multivariate analysis. Some guidelines for physicians. JAMA (1983) 0.88
Carotenoids, retinol, and vitamin E and risk of proliferative benign breast disease and breast cancer. Cancer Causes Control (1992) 0.87
Autologous humoral response to human gliomas and analysis of certain cell surface antigens: in vitro study with the use of microcytotoxicity and immune adherence assays. J Natl Cancer Inst (1980) 0.87
Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. Breast (2003) 0.87
Conservative treatment of early-stage breast cancer in a medically indigent population. J Natl Med Assoc (1995) 0.87
Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma. Surgery (1978) 0.87
Patterns of local-regional recurrence and results in Stages I and II breast cancer treated by irradiation following limited surgery. An update. Am J Clin Oncol (1984) 0.87
Solitary plasmacytoma. J Surg Oncol (1983) 0.86
Adjuvant postoperative radiation therapy for rectal adenocarcinoma. Am J Clin Oncol (1992) 0.86
Intraoperative electron beam radiation therapy for recurrent locally advanced rectal or rectosigmoid carcinoma. Cancer (1991) 0.86
Preoperative irradiation and fluorouracil chemotherapy for locally advanced rectosigmoid carcinoma: phase I-II study. Radiology (1993) 0.86
Intravenous dipyridamole thallium-201 SPECT imaging in patients with left bundle branch block. Clin Nucl Med (1990) 0.85
Prognosis of clinical stage I melanoma patients with positive elective regional node dissection. J Clin Oncol (1986) 0.85
Immediate breast reconstruction for stage III breast cancer using transverse rectus abdominis musculocutaneous (TRAM) flap. Ann Surg Oncol (1996) 0.85
Posthysterectomy megavoltage irradiation in the treatment of cervical carcinoma. Gynecol Oncol (1984) 0.84
Adjuvant chemotherapy in the node-negative breast cancer patient. Surg Clin North Am (1996) 0.84
Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys (1983) 0.84
Enteric duplication presenting as cystic tumors of the pancreas. Surgery (1997) 0.84
Effect of cyclophosphamide or x-rays on spontaneously occurring metastases from tumors transplanted into the tails of mice. Cancer Res (1981) 0.83
Anti-metastatic prostacyclins inhibit the adhesion of colon carcinoma to endothelial cells by blocking E-selectin expression. Clin Exp Metastasis (1996) 0.83
Intraoperative electron beam radiation therapy boost in the treatment of recurrent rectal cancer. Dis Colon Rectum (1980) 0.82
Non-metastatic locally advanced cancer of the breast treated with radiation. Int J Radiat Oncol Biol Phys (1984) 0.82
The effect of pentobarbital anaesthesia on the radiosensitivity of four mouse tumours. Int J Radiat Biol Relat Stud Phys Chem Med (1979) 0.82
Improved survival of patients with unresectable non-small-cell bronchogenic carcinoma by an innovated high-dose en-bloc radiotherapeutic approach. Cancer (1981) 0.82
Microcytotoxicity test: detection in sarcoma patients of antibody cytotoxic to human sarcoma cells. Science (1970) 0.81
Treatment of carcinoma of the breast in the older geriatric patient. Surg Gynecol Obstet (1991) 0.81
Preoperative irradiation for tethered rectal carcinoma. Radiother Oncol (1991) 0.81
Does preoperative needle localization lead to an increase in local breast cancer recurrence? Radiology (1988) 0.80
Implications for clinical management in patients with breast cancer. Long-term effects of reconstruction surgery. Cancer (1991) 0.80
Sensitivity and specificity of serum ribonuclease in the diagnosis of pancreatic cancer. Am J Surg (1980) 0.80
Cytotoxicity of human brain tumors by hematoporphyrin derivative. J Surg Res (1986) 0.80
Phase II trial of carboplatin in advanced breast carcinoma: a Cancer and Leukemia Group B Study. Cancer Treat Rep (1985) 0.79
Human astrocytoma: serum-mediated immunologic response. Cancer (1974) 0.79